IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) announced today that the European Commission has extended the Marketing Authorization for OZURDEX® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with visual impairment due to diabetic macular edema (DME) who are pseudophakic (have an artificial lens implant), or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.1 DME is a common complication with diabetes and is the leading cause of sight loss in patients with diabetes.2,3,4
“Through Allergan’s efficient R&D investment, we are able to continually bring forth innovative new treatment options for physicians and their patients while delivering value to our stockholders,” said David E.I. Pyott, Allergan’s Chairman of the Board and Chief Executive Officer. “Following the positive opinion from the European Union’s Committee for Medicinal Products for Human Use just last month, we are particularly pleased that with this license extension for OZURDEX® in Europe, in addition to the recent FDA approval in the United States, we are able to offer another important treatment option to help preserve vision for certain patients with DME.”
Help employers find you! Check out all the jobs and post your resume.
